Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

NCT03084237 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

652

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: HLX02
BIOLOGICAL: Herceptin®
DRUG: docetaxel

Sponsor

Shanghai Henlius Biotech